Hua Medicine Limited
17
2
2
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
18%
3 trials in Phase 3/4
7%
1 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes
Role: lead
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
Role: lead
Drug Interaction Study Between Dorzagliatin and Empagliflozin
Role: lead
A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes
Role: lead
Drug Interaction Study Between Dorzagliatin and Sitagliptin
Role: lead
A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers
Role: lead
Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
Role: lead
Long-term Efficacy and Safety of HMS5552 in T2DM Subjects
Role: lead
A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers
Role: lead
A Multi-center 12-week Study of HMS5552 in T2DM
Role: lead
DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin
Role: lead
DDI Study Between Dorzagliatin and Rifampicin
Role: lead
Human Mass Balance Study of HMS5552 in Healthy Subjects
Role: lead
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
Role: lead
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes
Role: lead
Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
Role: lead
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
Role: lead
All 17 trials loaded